Canada markets closed
  • S&P/TSX

    19,235.09
    -135.90 (-0.70%)
     
  • S&P 500

    3,783.28
    -7.65 (-0.20%)
     
  • DOW

    30,273.87
    -42.45 (-0.14%)
     
  • CAD/USD

    0.7346
    -0.0056 (-0.76%)
     
  • CRUDE OIL

    88.03
    +1.51 (+1.75%)
     
  • BTC-CAD

    27,323.09
    -463.89 (-1.67%)
     
  • CMC Crypto 200

    456.09
    -2.31 (-0.50%)
     
  • GOLD FUTURES

    1,725.00
    -5.50 (-0.32%)
     
  • RUSSELL 2000

    1,762.69
    -13.07 (-0.74%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • NASDAQ futures

    11,628.00
    -12.75 (-0.11%)
     
  • VOLATILITY

    28.55
    -0.52 (-1.79%)
     
  • FTSE

    7,052.62
    -33.84 (-0.48%)
     
  • NIKKEI 225

    27,120.53
    +128.32 (+0.48%)
     
  • CAD/EUR

    0.7427
    +0.0017 (+0.23%)
     

Sanofi CFO says stock price pummelling grossly overdone

·1 min read

FRANKFURT (Reuters) - Sanofi's finance chief said on Wednesday that a decline in the French company's share price in response to litigation threats and a cancer drug development setback was strongly exaggerated and posed a buying opportunity for savvy investors.

Sanofi earlier said it would stop further work on amcenestrant, once seen to have large potential against breast cancer, triggering a 5% drop in the share price. That compounded similar losses last week amid litigation concerns over an alleged cancer causing effect of heartburn drug Zantac.[L8N2ZT106]

Sanofi's share price was already not reflecting its earnings growth potential before last week, CFO Jean-Baptiste de Chatillon told Reuters.

"And now there's just a strong, strong disconnect. So I think some people will see it, and some investors will say that they will come back," the CFO added.

(Reporting by Ludwig Burger; Editing by Paul Carrel)